Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Nikolov

Showing results (121-130 of 123) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 123 results.
The Journal of Experimental Medicine|August 10, 2016
An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growthLakmali Atapattu, Nayanendu Saha, Chanly Chheang, et al.
Human Immunology|February 28, 2021
Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomesRachelle P Mendoza, William Fyke, David Daniel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2023
A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer TherapyAmr El Zawily, Frederick S Vizeacoumar, Renuka Dahiya, et al.
Pageof 13

Showing results (121-130 of 123) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 123 results.
The Journal of Experimental Medicine|August 10, 2016
An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growthLakmali Atapattu, Nayanendu Saha, Chanly Chheang, et al.
Human Immunology|February 28, 2021
Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomesRachelle P Mendoza, William Fyke, David Daniel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2023
A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer TherapyAmr El Zawily, Frederick S Vizeacoumar, Renuka Dahiya, et al.
Pageof 13